Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

Additionally, the court ruled that Exelixis' pharmaceutical composition patent (U.S. 11,298,349) is not invalid and not infringed by MSN's proposed ANDA product. "We are pleased with the court's ...

Your Account Isn't Verified! In order to create a playlist on Sporcle, you need to verify the email address you used during registration. Go to your Sporcle Settings to finish the process.

This project is now archived, all future development is now on our new python installer which has more features etc. See the new project here: https://github.com ...

The best logo maker helps you craft the right branding for your business - even if you've never designed a logo before. Our team of expert reviewers have tested the best free logo makers and the ...

The most notable change is to the company’s logo: what was previously a sans-serif wordmark styled as “Moz://a” has been updated to correctly spell out the Mozilla name, featuring a new ...

The firm anticipates a deceleration in the year-over-year growth of Exelixis's cancer drug, Cabometyx, projecting it to a mid-single digit trend for the years 2024 and 2025. Additionally, concerns ...

The firm anticipates a deceleration in the year-over-year growth of Exelixis's cancer drug, Cabometyx, projecting it to a mid-single digit trend for the years 2024 and 2025. Additionally ...

The company has a new logo, designed by Pentagram, that looks incredibly plain — especially compared to previous iterations of the logo that featured a rakish slant, two shades of blue ...

Exelixis (NASDAQ:EXEL) has released additional phase 3 data on Cabometyx (cabozantinib) in individuals with pancreatic neuroendocrine tumors (pNET) and with advanced extra-pancreatic ...